Gremlin-1 antagonist for the prevention and treatment of cancer | Patent Number 12162934

US 12162934 B2
Application Number17253660
Publication NumberUS 20210253688 A1
Pendency5 years, 5 months, 27 days
Filled DateJun 18, 2019
Priority DateJun 18, 2019
Publication DateAug 19, 2021
Expiration DateJun 17, 2039
Inventor/ApplicantsGareth Charles Glyndwr Davies
Simon Leedham
VASILIOS PANAGOPOULOS
Kimberley Clark
SIMON LEEDHAM
ANDREW ZANNETTINO
GARETH CHARLES GLYNDWR DAVIES
DUNCAN HEWETT
Duncan Hewett
KIMBERLEY CLARK
Vasilios Panagopoulos
Andrew Zannettino
ExaminesLOCKARD, JON MCCLELLAND
Art Unit1647
Technology Center1600
Assignments
The University Of Adelaide
Current
Ucb Pharma SaThe University Of Adelaide
Original
Ucb
Original
Oxford University Innovation Limited
Original
Law Firm
You must be logged in to view
Login
Attorneys
Subscription-Only
View Concierge Program
Patent Prosecution report image

Empower your practice with Patexia Publication Prosecution IP Module.

Get access to our exclusive rankings and unlock powerful data.
Check our Latest ReportPurchase IP Module

Looking for a Publication Attorney?

Get in touch with our team or create your account to start exploring a network of over 120K attorneys.